Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.
Biologic Treatments for Moderate to Severe Atopic Dermatitis
Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.
Observational study shows high heart disease risk in severe and predominantly active atopic eczema.
For some patients with moderate to severe atopic dermatitis, the combination of dupilumab and corticosteroids may be necessary to control flares, a new study shows. Dupilumab is a proven treatment for AD, so where do we go from here? A physician writing in BJD suggests predictive modeling.
Three patients achieve 80-100 percent clearance of moderate-to-severe dyshidrosis of the hands and palms after treatment with dupilumab.
Symptomatic relief remains out of reach for many who suffer chronic pruritis. Without drugs specifically approved to treat chronic itch, providers and patients rely on therapies with limited efficacy. Here’s an update of two important clinical trials.
A phase two study of adults with moderate-to-severe atopic dermatitis shows that once-daily oral Janus kinase (JAK) 1 and 2 inhibitor baricitinib relieved itch and improved sleep, a study shows.
The transcription factor "retinoid-related orphan receptor-alpha" (RORA) has been identified as a regulator of T regulatory (Treg) genes responsible for suppressing allergic skin inflammation, researchers report.
The duration of methotrexate administration proves to be longer than that of cyclosporine in atopic dermatitis, according to a small study that compared the two first-line immunosuppressive treatments for atopic dermatitis.
New data and status updates for atopic dermatitis treatments in clinical trials will be presented at the American Academy of Dermatology annual meeting in San Diego this week. In this article, we offer some highlights.